… autophagy, may provide a strategy for development of novel anticancer agents with an …
of antitumor activity and potential side effects associated with our dual inhibitors. This will be …

… dual inhibitor has displayed anti-tumor activity in preclinical cancer models [14]. In the current
study, we explored its activity … the anti-cancer activity by a number of mTOR inhibitors [18]. …

… C1) groups caused dramatic drops in anticancer activities, while the replacement of the N,N…
activities as compared to CAA. In addition, C5 displayed dual Topo I and II inhibitory activities …

… and the PI3K/mTOR dual inhibitor PF-04691502. We analyzed the anticancer effect of siRNA
… siRNA VEGF potentiates the PF-04691502 anticancer activity against non–small-cell lung …

… In summary, we have successfully designed and synthesized novel dual HDAC/CDK
inhibitors. The representative compounds (7c and 14a) displayed potent antiproliferative activities …

… The conjugated N–N–S or N–N–O tridentate ligand system of thiosemicarbazides and
semicarbazones were considered as essential moieties for anticancer activities through inhibiting …

2,4-Disubstituted thiophene derivatives were synthesized and assessed for antiinflammatory
and anti-cancer activities by targeting two important enzymes of the arachidonic acid …

… inhibitor palbociclib and the dual mTOR kinase inhibitor MLN0128 had synergistic anti-cancer
activity … This drug combination has a potent synergistic inhibitory effect on pRb-expressing …

… Apitolisib effectively inhibits PI3Kα with IC 50 of picomolar range and mTOR with IC 50 of
subnanomolar range, it also exhibited excellent in vivo anticancer activity by sustained …

… for their anticancer activity against 60 human tumour cell lines by NCI (USA). Compound 7d
proved prominent anticancer activity. It showed 1.6-fold more potent anti-proliferative activity …